Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Depression 3 Anxiety Disorders 3 Neoplasms 2 Ovarian Neoplasms 1 Opioid-Related Disorders 1 Neoplasm Metastasis 1 Depressive Disorder 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Agnosia 1

Interventions

Morphine 2 Bupivacaine 2 Anesthesia, Local 2 Analgesia, Epidural 2 engage 8200 1 Transdermal Patch 1 Touch 1 Telemedicine 1 Surgical Instruments 1 Ropivacaine 1 Radiosurgery 1 Radiofrequency Ablation 1 Psilocybin 1 Palliative Care 1 Methods 1 Ketorolac 1 Hydromorphone 1 Exercise 1 Epinephrine 1 Electroencephalography 1 Dipyrone 1 Cryosurgery 1 Clonidine 1 Capsaicin 1 Botulinum Toxins, Type A 1 Anesthesia, Spinal 1 Acupuncture Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Agnosia × Psilocybin × Clear all

NCT06001749 2025-12-16

Psilocybin in Cancer Pain Study

Dana-Farber Cancer Institute

Phase 2 Recruiting

Agnosia, Opioid-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡